164 related articles for article (PubMed ID: 32350606)
21. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
[TBL] [Abstract][Full Text] [Related]
22. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
23. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
24. SPINK1 protein expression and prostate cancer progression.
Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
[TBL] [Abstract][Full Text] [Related]
25. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
26. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
27. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
29. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
30. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
Shah RB; Bentley J; Jeffery Z; DeMarzo AM
Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy.
Fragkoulis C; Glykas I; Tzelves L; Stamatakos PV; Papadopoulos G; Stathouros G; Dellis A; Ntoumas K; Kostopoulou A; Deliveliotis C; Papatsoris A
Arch Ital Urol Androl; 2022 Dec; 94(4):390-395. PubMed ID: 36576468
[TBL] [Abstract][Full Text] [Related]
33. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
34. Molecular alterations in prostate cancer and association with MRI features.
Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
[TBL] [Abstract][Full Text] [Related]
35. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
[TBL] [Abstract][Full Text] [Related]
36. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
37. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
38. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
39. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.
Noh BJ; Sung JY; Kim YW; Chang SG; Park YK
Oncol Lett; 2016 Jun; 11(6):3621-3630. PubMed ID: 27284364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
